Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888
- PMID: 37794195
- DOI: 10.1007/s12032-023-02181-9
Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888
Abstract
Combination therapy has been frequently preferred in treating various types of cancer in recent years. Targeted cancer therapy has also become one of the remarkable treatment modalities. Therefore, the aim of the study to investigate its cytotoxic and apoptotic effects on liver cancer cell lines by combining the classical chemotherapeutic drug doxorubicin (DOX) and a targeted agent, the new generation HSP90 inhibitor XL-888. The molecular docking method was used to predict the binding conformation of XL-888 on the human Hsp90. The single and combined cytotoxic effects of DOX and XL-888 on liver cancer cell lines HepG2 and HUH-7 were determined by MTT assay. The effect of the combined use of two drugs was evaluated using Chou and Talalay method. The levels of apoptotic genes and heat shock proteins gene and protein expression levels were investigated by quantitative real-time polymerase chain reaction and western blotting, respectively. Molecular docking results showed that XL-888 selectively binds to the ATP binding pocket of HSP90 with an estimated free binding energy of - 7.8 kcal/mol. DOX and XL-888 and their combination showed dose-dependent cytotoxic effect. The combination of drugs showed a synergistic effect on both cell lines. The results revealed that the combination of DOX and XL-888 potently induced apoptosis in liver cancer cell lines rather than using drugs alone. The combined treatment of DOX and XL-888 demonstrated synergistic cytotoxic and apoptotic effects on liver cancer cell lines, presenting a promising approach for combination therapy in liver cancer.
Keywords: Combination treatment; Doxorubicin; HSP90 inhibition; Liver cancer; XL-888.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3249-3259. doi: 10.1007/s00210-023-02807-9. Epub 2023 Nov 2. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37917369
-
Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis.Carcinogenesis. 2018 Mar 8;39(3):458-470. doi: 10.1093/carcin/bgy003. Carcinogenesis. 2018. PMID: 29329420
-
Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl.PLoS One. 2012;7(12):e51764. doi: 10.1371/journal.pone.0051764. Epub 2012 Dec 11. PLoS One. 2012. PMID: 23240061 Free PMC article.
-
Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.Mol Biol Rep. 2021 Apr;48(4):3439-3449. doi: 10.1007/s11033-021-06392-z. Epub 2021 May 17. Mol Biol Rep. 2021. PMID: 33999319
-
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.Int J Mol Sci. 2017 May 12;18(5):1048. doi: 10.3390/ijms18051048. Int J Mol Sci. 2017. PMID: 28498322 Free PMC article.
Cited by
-
Molecular pathway of anticancer effect of next-generation HSP90 inhibitors XL-888 and Debio0932 in neuroblastoma cell line.Med Oncol. 2024 Jul 3;41(8):194. doi: 10.1007/s12032-024-02428-z. Med Oncol. 2024. PMID: 38958814 Free PMC article.
References
-
- Hajiasgharzadeh K, Somi MH, Shanehbandi D, Mokhtarzadeh A, Baradaran B. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma. J Cell Physiol. 2019;234:3263–76. https://doi.org/10.1002/jcp.27015 . - DOI - PubMed
-
- Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;460:1–9. https://doi.org/10.1016/j.canlet.2019.114428 . - DOI - PubMed
-
- Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239–45. https://doi.org/10.1097/MCG.0b013e3181d46ef2 . - DOI - PubMed
-
- Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol. 2017;9:907–20. https://doi.org/10.4254/wjh.v9.i21.907 . - DOI - PubMed - PMC
-
- Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today. 2017;22:270–81. https://doi.org/10.1016/j.drudis.2016.11.005 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical